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Abstract
Background: A temporary loop ileostomy, which is used to decrease the risk of symptomatic anastamotic leakage
after anterior resection and total mesorectal excision (TME), is traditionally closed without any mesh. However, as 44%
of incisional site hernias need further repair after stoma closure, attention has increasingly been paid to the use of
mesh. Research on the prevention of these hernias is scarce, and no studies comparing different meshes exist.
Method/Design: The Preloop trial (Clinical Trials NCT03445936) is a prospective, randomized, controlled, multicenter
trial to compare synthetic mesh (Parietene Macro™, Medtronic, Minneapolis, MN, USA) and biological implants
(Permacol™, Medtronic) at a retromuscular sublay position for the prevention of incisional site hernias after loop-
ileostomy closure. The main endpoints in this trial are infections at 30-day follow-up and the incidence of hernias
clinically or on CT scan at 10 months after closure of the stoma. The secondary endpoints are other complications
within 30 days of surgery graded with the Clavien-Dindo classification, reoperation rate, operating time, length of stay,
quality of life measured with RAND-36, and incidence of hernia over a 5-year follow-up period. A total of 100 patients
will be randomized in a 1:1 ratio.
Discussion: This is a pilot trial that will be undertaken to provide some novel evidence on the safety profile and
efficiency of both synthetic mesh and biological implants for the prevention of incisional hernias after closure by
temporary loop ileostomy. The hypothesis is that synthetic mesh is economical but equally safe and at least as effective
as biological implants in hernia prevention and in contaminated surgical sites.
Trial Registration: ClinicalTrials.gov, NCT03445936. Registered on 7 February 2018.
Keywords: Loop-ileostomy closure, Rectal cancer, Hernia prevention, Synthetic mesh, Biological implant
Background and rationale
Anastomotic leakage is a major cause of morbidity after
sphincter-saving anterior resection and total mesorectal
excision (TME), with a reported incidence in a large
meta-analysis of 11% [1]. A temporary diverting stoma
has been shown to significantly decrease the risk of
symptomatic anastomotic leakage and the need for reop-
eration in meta-analyses [2–5]. Defunctioning loop ileos-
tomy is superior to loop colostomy in terms of a lower
surgical complication rate and fewer parastomal and in-
cisional hernias and surgical site infections [6, 7].
In a recently published retrospective study by Juratli et al.,
the incidence of incisional hernias after loop-ileostomy
closure detected by computed tomography (CT) scan
12–24 months later reached 21.5% [8]. Another retro-
spective cohort showed an incisional hernia incidence
of 13.5% after loop-ileostomy closure after a median
follow-up of 20 months [9]. Of these clinically de-
tected incisional hernias, 44% needed further surgical
repair upon meta-analysis [10]. The true rate of inci-
sional hernias might be higher, though, as the inci-
dence of hernias increases over time [11, 12].
So far, the fear of infectious complications has discour-
aged the use of synthetic mesh in contaminated surgical
fields. Nevertheless, the infection rate of patients with syn-
thetic prophylactic mesh applied in contaminated surgical
fields is similar to that of controls without the mesh at the
time a permanent stoma was created [13–16]. The use of
synthetic meshes as prophylaxis has also been shown to be
safe in other contaminated abdominal surgery sites [15, 17].
* Correspondence: Elisa.makarainen-uhlback@ppshp.fi
1Oulu University Hospital, PL 10, 90029 OYS, Oulu, Finland
Full list of author information is available at the end of the article
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Mäkäräinen-Uhlbäck et al. Trials          (2018) 19:617 
https://doi.org/10.1186/s13063-018-2977-9
There are only a few previous studies on prophylactic
mesh utilization at the time of stoma closure. Biological
mesh has been demonstrated to be safe in terms of com-
plications [18, 19] and effective in preventing hernias
[20]. However, no randomized controlled trials (RCTs)
have been published. Reinforcement of Closure of Stoma
Site (ROCSS) Collaborative and the West Midlands Re-
search Collaborative has recently published a protocol
for an RCT comparing a standard suture closure to
mesh reinforcement with biological intra-abdominal
mesh after stoma closure [21]. Research on synthetic
meshes in the same context is even rarer. An Australian
study group found a significant reduction in the rate of
incisional hernias following mesh placement without in-
creasing the rate of infection complications, despite the
use of prosthetic material in the contaminated surgical
site [22]. In a register study, the application of synthetic
mesh was found to be both safe and effective in prevent-
ing incisional site hernias after stoma closure [23]. There
have been no trials comparing biological implants and
synthetic mesh on incisional hernia prophylaxis.
Macroporous monofilament polypropylene mesh (Par-
ietene Macro™, Medtronic) has previously been shown to
be safe in contaminated surgical sites according to satis-
factory preliminary results of the PREVENT trial in
parastomal hernia prophylaxis [24]. Likewise, there have
been no trials on the use of porcine dermal collagen im-
plants to prevent hernias, although they have been
widely studied for ventral hernia repair [25].
The ideal location for the prophylactic mesh is still
unclear. In a recent meta-analysis that included all
types of postoperative ventral hernias, the sublay loca-
tion of mesh was associated with the lowest rate of
infection and recurrence [26]. Based on the results of
a meta-analysis on parastomal hernia prevention, the
sublay position of a non-absorbable prophylactic mesh
is preferred [16].
Objectives
The objective of the Preloop trial is to compare synthetic
mesh (Parietene Macro™, Medtronic) and biological im-
plants (Permacol™, Medtronic) for the prevention of inci-
sional site hernias after temporary loop-ileostomy
closure (see Table 1). Our hypothesis is that synthetic
mesh is equally safe and effective as biological implants
in incisional site hernia prophylaxis, and that they both
can significantly reduce the rate of incisional hernias de-
tected in previous studies. Its lower price also makes
synthetic mesh a more lucrative option. By demonstrat-
ing that synthetic mesh is equal to biological implants in
terms of safety and efficiency, this study might encour-
age investigators to design upcoming trials that use syn-
thetic materials in contaminated fields. As previous
studies are scarce, the Preloop trial was planned as a
pilot study to provide preliminary results on the safety
and efficiency of both devices used in the study.
Trial design
The Preloop trial (see also Fig. 1) is a prospective, ran-
domized, controlled, multicenter study comparing two
devices (synthetic mesh, Parietene Macro™, Medtronic;
and biological implant, Permacol™, Medtronic) in pre-
venting ileostomy site hernias, including in patients who
have undergone low anterior resection and TME for rec-
tal adenocarcinoma with diverting loop ileostomy. The
trial is independent from any kind of industrial
sponsorship.
Devices trialed
Parietene Macro™ (Medtronic) is a macroporous mono-
filament polypropylene synthetic mesh widely used in her-
nia repair. Permacol™ is an acellular porcine dermal
collagen implant designed for hernia repair (see Table 1).
The size of the biological implant selected for this study
(Permacol™, Medtronic) reflected a compromise of price.
As the price of an implant increases significantly the larger
it is, the chosen 10 cm in length and 5 cm in width repre-
sents a realistic option for use in general practice, if it is
shown to be both effective and safe. The significantly
more affordable synthetic mesh (Parietene Macro™, Med-
tronic) has been trimmed to fit the retromuscular space in
width, as would be done in general everyday practice.
Methods
Study setting
This study will be completed in several university and
central hospitals in Finland: Oulu University Hospital,
Turku University Hospital, Tampere University Hospital,
Kuopio University Hospital, Jyväskylä Central Hospital,
and Seinäjoki Central Hospital.
Table 1 Comparison of devices in Preloop trial
Comparison of devices Parietene Macro Permacol
Manufacturer Medtronic Medtronic
Mesh type Synthetic Biological implant
Material Macroporous monofilament polypropylene mesh porcine dermal collagen implant
Size Trimmed to fit retromuscular space, original size before trimming 10 × 15 cm length 10 cm, width 5 cm
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Eligibility criteria
Inclusion criteria
 Anterior resection and TME with temporary loop
ileostomy for rectal adenocarcinoma without any
adjuvant oncological treatment
 Age 18 years or older
 Life expectancy of at least 12 months
 Signed informed consent with agreement to attend
all study visits
 Loop-ileostomy closure within 2–4 months after the
primary operation
Exclusion criteria
 Presence of a comorbid illness or condition that
would preclude surgical treatment (American
Society of Anesthesiologists [ASA] grade 4–5).
 Concurrent or previous malignant tumors within 5
years before study enrollment
 Presence of T4b tumors necessitating a multi-organ
resection
 Patients treated with postoperative adjuvant
chemotherapy
 Patients undergoing emergency procedures
 Primary rectal surgery along with major
concomitant procedures (e.g. hepatectomies, other
intestinal resections).
 Metastatic disease with life expectancy of less than
12 months
 Pregnancy or suspected pregnancy
All subjects who have had anterior resection and TME
for rectal adenocarcinoma at any of the study sites and
have not received any adjuvant oncological treatment
due to routine protocol of rectal cancer treatment will
be considered for inclusion at 1-month follow-up at the
outpatient department after the primary operation. The
current practice at Oulu University Hospital is to close
temporary loop ileostomy by suturing the fascial defect
without a mesh at either 2–4 months after uncompli-
cated anterior resection or about 8–12 months after an-
terior resection after adjuvant oncological treatment has
been accomplished. A full-body CT scan is part of the
1-year follow-up protocol after anterior resection for
rectal adenocarcinoma. Therefore, only subjects not re-
ceiving adjuvant treatment can be enrolled in the study
without having any additional radiation and still undergo
a CT scan for both cancer follow-up and detection of
possible incisional hernias about 1 year from each oper-
ation. After receiving proper information on the possible
advantages and disadvantages of intervention, and after
voluntarily signing the informed consent form, the sub-
jects will be enrolled in the Preloop trial.
Participating investigators are qualified colorectal or
general surgeons experienced in the surgical management
of patients with temporary stomas. Further, all
Fig. 1 Flowchart
Mäkäräinen-Uhlbäck et al. Trials          (2018) 19:617 Page 3 of 8
participating surgeons are experienced in the relevant
technique for loop-ileostomy closure procedures and the
use of retromuscular meshes. The technique that will be
used to apply both the synthetic mesh and the biological
implant is identical. Surgeon contributions to the study
will be limited to no less than 10 cases per hospital, and
all attending hospitals will be directed to assign the opera-




Loop ileostomy will be established at anterior resection
on a site previously marked by a trained ostomy nurse.
The bowel forming the stoma will be everted about 1–
2 cm above the skin and attached by Monocryl 4–0 su-
tures to the edges of the skin.
Closure of stoma site
The closure of the temporary loop ileostomy will be per-
formed 2–4 months after uncomplicated anterior resec-
tion on subjects who had since received no adjuvant
treatment. The re-establishment of intestinal continuity
will be achieved through the ostomy trephine either by
staples or by hand-sewn anastomosis, according to the
surgeon’s preference, and the bowel will be positioned
back into the peritoneal cavity. Midline laparotomy will
be used in the case of extensive bowel adhesions. The
posterior rectus sheath will be closed with interrupted
2.0 polydioxanone sutures (PDS Plus Antibacterial
Suture, Ethicon, Johnson & Johnson, Somerville, NJ,
USA). The retromuscular space will be dissected with
monopolar diathermy or another suitable energy device
to create the space for the mesh. In the first group, a
biological implant measuring 10 cm in length and 5 cm
in width with the corners slightly curved (Permacol™,
Medtronic) will be placed in the retromuscular space
established as described above. In the second group, a
lightweight polypropylene mesh (Parietene Macro™,
Medtronic) with measures matching the retromuscular
space will be placed similarly into the retromuscular
sublay position. Four interrupted 2.0 polydioxanone su-
tures (PDS Plus Antibacterial Suture, Ethicon, Johnson
& Johnson), one in each corner of the mesh, will be used
to fix the mesh to the underlying posterior rectus sheath.
After mesh fixation, the anterior rectus sheath will be
closed with interrupted 0 polydioxanone sutures (PDS
Plus Antibacterial Suture, Ethicon, Johnson & Johnson).
The skin defect will be closed by a running subcutane-
ous purse-string suture with a 2.0 polyglactin thread
(Coated Vicryl Plus Antibacterial Polyglactin 910 Suture,
Ethicon, Johnson & Johnson).
As a preoperative antibiotic, prophylaxis cefuroxime
1.5 g and metronidazole 500 mg administered
intravenously (i.v.) will be used. Patients with a body
mass index (BMI) ≥ 30 will receive cefuroxime 3 g and
metronidazole 1 g i.v. If the patient has had a previous
allergic reaction to primary prophylactic antibiotics, clin-
damysin 600 mg i.v. (or, in case of BMI ≥ 30, clindamysin
900 mg i.v.) and ciprofloxacin 400 mg i.v. will be admin-
istered. No mechanical bowel preparation will be given.
Outcomes
The main endpoints of the study will be the surgical site
infection rate and the incidence and extent of stoma site
incisional hernia, either symptomatic or asymptomatic,
detected clinically and/or radiologically 10 months after
surgery. All patients will have had a full-body CT scan
and will be met in the outpatient clinic, according to
hospital protocol, 12–14 months after the anterior resec-
tion. During this visit, the condition of the previous loop
ileostomy scar will be assessed, and a clinical estimation
of the presence of incisional hernia will be made. All
symptoms in this regard will be recorded. As a CT scan
at about a 1-year follow-up is part of the follow-up
protocol after anterior resection for rectal adenocarcin-
oma, patients will be exposed to no additional radiation
within the trial, and therefore only subjects not receiving ad-
juvant therapy will be enrolled. All CT scans will be analyzed
by the same radiologist, who will be blinded to the type of
mesh used. The data collected will include exact measures
of fascial defect, location of the defect, content and extent of
the hernia sac, and the incidence of other hernias.
Surgical site infection has been defined in accordance
with the Centers for Disease Control and Prevention
(CDC) Surgical Site Infection Event. Any suspicion of surgi-
cal site infection or other complication during the primary
hospital stay after loop-ileostomy closure will be assessed
by an experienced colorectal/general surgeon who will not
have been involved in the Preloop trial and will have been
blinded to the mesh used to avoid bias. In the same man-
ner, all concerns regarding complications or harmful events
after hospitalization will be referred to second opinion.
The European Hernia Society definition of incisional
site hernia has been applied [27], and the Clavien-Dindo
classification of complications will be used to ensure
proper classification. All data concerning operations dur-
ing the hospital stay, recovery, and complications will be
recorded on an electronical case report form (eCRF) de-
signed for this study.
Costs will be monitored and analyzed in detail. Direct
costs comprise the price of the mesh, the length of the
hospital stay, and the treatment of possible complica-
tions. An estimation of the facilities used, including op-
erating room time, will also be made. Indirect costs will
mainly comprise the length of sick leave.
The secondary endpoints of the study are as follows:
Mäkäräinen-Uhlbäck et al. Trials          (2018) 19:617 Page 4 of 8
a) Clavien-Dindo grade I–V complications within 30
postoperative days
b) Reoperation rate
c) Operative time (minutes)
d) Length of stay (LOS, days)
e) Quality of life (QoL) measured by the 36-item
RAND health survey (RAND-36)




– Other significant diseases and medications
– Smoking history
– Previous hernias, both symptomatic and
asymptomatic, operated or unoperated
– Operative details on anterior resection, including
anastomosis technique, distance from the anus,
complications, and problems with the formation
of stoma
– Tumor-node-metastasis (TNM) classification of the
rectal cancer
– Quality of life measured by RAND-36 questionnaire
Intervention data
– Antibiotic prophylaxis used
– Operative time, operation room time, time to apply
the mesh/implant
– Technique and approach used to close the stoma
and re-establish intestinal continuity
Post-intervention data
– Length of hospital stay
– All complications measured by the Clavien-Dindo
classification
– Surgical site infection classified by the CDC
– Demand for re-operation and mesh removal
– Re-admissions
– RAND-36 questionnaire
– Clinically and/or CT-detectable hernia
– Hemoglobin, carcinoembryonic antigen (CEA)
– Bowel function
– State of incisional wound for loop-ileostomy closure
when leaving the hospital
Participant timeline
Randomization started in February 2018 at Oulu University
Hospital and will last for 2 years. The follow-up schedule is
presented in Table 2. Short-term results and complications
will be monitored at discharge and 1 month after the oper-
ation. CT scans to detect subclinical hernias besides clinical
evaluation will be performed 10 months after stoma closure
as part of the routine protocol of rectal adenocarcinoma
follow-up.
Sample size
Two of the previously published retrospective studies re-
ported the incidence of incisional hernias to be 13.5–
21.5% on short-term follow-up after closure by suturing
[8, 9]. Likewise, the number of hernias after closure with
mesh has been very few in short-term follow-up [20, 22].
We assume that the hernia rate after closure by suturing
detected in previous studies can be significantly dimin-
ished to about 5% with a prophylactic synthetic mesh or
biological implant on long-term follow-up. The aim of
the study is to generate preliminary results showing syn-
thetic mesh is non-inferior to biological mesh. Assuming
α = 0.05 and a power = 80% for incisional hernias and
with 5% non-inferiority marginal, we would need 235
patients per group. Although previous studies on both
biological implants and synthetic meshes have raised no
concerns on the safety of the meshes [18–20, 22, 23],
the use of synthetic meshes in contaminated surgical
Table 2 Schedule of events





QoL X X X X X
Procedure details X
CT scan findings X
Protocol deviation X* X* X* X* X* X* X* X*
Complications X* X* X* X* X* X* X*
Study exit form X**
*Complete if applicable
**Complete when lost to follow-up, consent withdrawal, or when the subject has completed all study-related visits
CT computed tomography, QoL quality of life
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sites continues to be widely avoided in clinical practice,
and no comparative studies on incisional hernia prophy-
laxis after temporary stoma closure exist. That said, we
assume there is no difference in infectious complications
between the meshes.
As this is a pilot study, each group will comprise 45
patients. Considering a possible 10% drop-out rate, our
aim is to have 50 patients per group. Therefore, the esti-
mated sample size of 50 in each group should give a reli-
able preliminary estimation of the safety and efficiency
of both meshes for further studies.
Recruitment
All subjects fulfilling the inclusion criteria at each research
site will be considered to participate in the trial at 1-month
follow-up after anterior resection. An anonymous record
will be kept prospectively on all subjects fulfilling the inclu-
sion criteria but not attending, either by declining or for
any other reason, for later assessment of selection bias.
Assignment of interventions
Allocation
Subjects will be randomly allocated to study groups
according to a computer-generated list compiled by a
biostatistician otherwise uninvolved in the clinical care
of trial patients.
Randomization will be performed in blocks, where the
block size will vary randomly between two, four, and six.
A separate randomization list will be created for each
center, and randomization will be accomplished by elec-
tronic software. Randomization will be performed after
confirmation of patient eligibility and willingness to
participate.
Blinding
The subjects will be blinded to the method used during
their hospital stay. After hospitalization, blinding will
become impossible to maintain reliably due to a nation-
wide medical database directly accessible to patients.
The surgeon who will meet the patients at 10-month
follow-up will not be the same as the operating phys-
ician and will be blinded to the method used. The radi-
ologist will also be blinded to the method used.
Data collection, management, and analysis
Data collection methods
All data will be collected prospectively on an electronic
database designed for this study. The RAND-36 ques-
tionnaire to be used in this study has been well docu-
mented previously.
The reasons for withdrawal will be documented care-
fully. The investigator will attempt to contact the subject
at least three times prior to designating them as lost to
follow-up. The investigator will document the date and
type of attempted communication. If a subject cannot be
reached during the visit window, a missed visit will be
recorded; after three consecutive missed visits, the sub-
ject will be considered lost to follow-up, and a study exit
form will be completed in the eCRFs. Any data on sub-
ject participation and procedures until their withdrawal
will be analyzed within the research.
Data management
All data will be handled with utmost confidentiality. Per-
mission for the study register has been submitted to
Oulu University Hospital, and a description of the regis-
ter has been provided.
Data monitoring
There is no data monitoring committee named in this trial.
All complications and harmful events will be carefully
reported using specific eCRFs, and serious events will be re-
ported to the principal investigator immediately. As previous
studies on synthetic mesh in particular are scarce, a prelimin-
ary safety analysis at 30-day follow-up will be made on 20 pa-
tients on each group. Any serious concern raised at any
point in the study on the safety of the meshes will result in
the consideration of preliminarily aborting the study.
Statistical methods
The main endpoints are the presence (proportion) of
stoma site incisional hernias with 95% confidence inter-
vals for both groups at 10-month follow-up, and the in-
cidence of surgical site infection at 30 days after the
closure of the stoma. Secondary outcomes are the pres-
ence of stoma site incisional hernias at 3- and 5-year
follow-up, the relative improvement to QoL during the
follow-up, Clavien-Dindo classification of complications
at 30 days postoperatively, operation time, length of hos-
pital stay, and reoperation rate.
Between-group comparisons of continuous variables will
be performed by Student’s t test or Mann-Whitney U test,
the latter of which will be used if heterogeneous variances
persist. Categorical data will be compared using χ2 or
Fisher’s exact test. Repeatedly measured continuous data
will be analyzed by a linear mixed model (LMM) using in-
dividuals as random effects. The covariance pattern for
the LMM was chosen according to Akaike’s information
criteria. Two-tailed p values will be reported. Analyses will
be performed using SPSS (version 24 or higher) (IBM
Corp., Armonk, NY, USA) for Windows and SAS (version
9.4 or higher) (SAS Institute, Cary, NC, USA).
Ethics and dissemination
Research ethics approval
This study follows the Declaration of Helsinki on medical
protocols and ethics, and the study’s protocol has been ap-
proved by the Ethics Committee of Oulu University Hospital
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(reference number 2/2018). Each participating hospital ap-
plied for study permission at their unit.
Protocol amendments
Important protocol modifications will be communicated
to the Oulu University Hospital Ethics Committee by
amendments. All modifications will also be registered at
Clinical Trials.
Confidentiality
Patient confidentiality will be strictly maintained. Patients
will be pseudonymized by study identification numbers, and
all data will be handled without using names or personal
social security numbers. Access to patient records will be
limited to the study group and the investigator-delegated
study coordinator.
Discussion
The true rate of incisional site hernias after temporary
loop-ileostomy closure may be underestimated. The inci-
dence ranges from 0 to 50% in previous studies, and up
to 44% of these hernias might need further operation
[10]. The rising trend of sphincter-saving procedures
may increase the need to temporary stomas and their
closure in the near future. Yet, limited data have been
published on the appropriate technique for hernia pre-
vention after temporary stoma closure. Previously, syn-
thetic mesh was contraindicated in contaminated
surgical fields, but there is growing evidence for the safe
prophylactic use of synthetic meshes in contaminated
surgical sites [17, 28]. Previous studies on hernia preven-
tion after temporary stoma closure have compared the
use of either synthetic or biological mesh to conven-
tional suture closure, showing a significant reduction in
hernia incidence. Additionally, hernia prevention with
either synthetic mesh or biological implants is becoming
increasingly popular and more utilized in gastrointestinal
and abdominal wall surgery. Therefore, the current trial
will focus on generating preliminary information on the
most economic, effective, and safe method to prevent in-
cisional hernias by comparing synthetic mesh to bio-
logical implants.
Blinding of the study is not possible In case of severe
complications requiring re-operation, it is crucial to have
direct access to all technical aspects of primary operation
at all times. Patients will be blinded to the method used
during their hospital stay, but it is impossible to control
blinding after discharge due to the patient-accessible
national medical database, which includes all medical re-
cords regarding patients.
This is the first randomized, controlled study to com-
pare biological implants and synthetic mesh to prevent in-
cisional hernias after loop-ileostomy closure. The selected
group of patients will be as homogenous as possible, since
they all will have undergone a low anterior resection for
rectal adenocarcinoma before enrollment. We assume
there will be no unexpected complications due to mesh
reinforcement, and that a significant number of hernias
can be prevented with either synthetic mesh or biological
implants. As previous studies are still few, the Preloop trial
was designed as a pilot trial to provide preliminary infor-
mation to form the basis for future trials.
Biological implants have previously been widely consid-
ered the first choice for contaminated surgical fields des-
pite their high price. If synthetic mesh can be shown to be
equally safe and effective in preventing hernias, it will also
become a more lucrative choice not only for preventing
incisional site hernias after temporary stoma closure, but
also for future trials on hernia prevention in other con-
taminated surgical sites. This research will provide novel
preliminary information on both the short- and long-term
effects and safety of the two prophylactic devices studied
to prevent incisional site hernias after stoma closure.
Trial status
Approval by the Ethics Committee at Oulu University
Hospital was received (reference 2/2018), and patient re-
cruitment at Oulu University Hospital started in February
2018. Seinäjoki Central Hospital enrolled its first patients
in March 2018, and other hospitals will start the trial dur-
ing autumn 2018.
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